Imidazolone derivatives
AssigneePfizer Inc.
InventorsJohn L. Belletire, Reinhard Sarges
Life of this patent
Estimating the term…
Abstract
A series of novel spiro-imidazolone compounds and their pharmaceutically acceptable acid addition salts are disclosed. These particular compounds are useful in therapy as agents for the control of certain chronic diabetic complications. 3',4'-Dihydro-spiro-[imidazolidine-4,1'(2'H)naphthalene]-5-one represents a typical and preferred member compound. Methods for preparing all these compounds from known hydantoin starting materials are provided.
Claims4
A method for treating a diabetic host to prevent or alleviate diabetes-associated chronic complications arising in said host, which comprises administering to said diabetic host an effective amount of a compound selected from the group consisting of spiro-imidazolone bases of the formula:
- ##STR5## and the pharmaceutically acceptable acid addition salts thereof, wherein X is hydrogen and X.sup.1 is hydrogen, fluorine, chlorine, bromine, lower alkyl or lower alkoxy;
- or
- X and X.sup.1, when taken separately, are each chlorine, lower alkyl or lower alkoxy, and when taken together at adjacent positions of the molecule are --OCH.sub.2 (CH.sub.2).sub.n O--;
- Y is --(CH.sub.2).sub.n --;
- and
- n is zero or one.
Dependencies are inferred from the claim text.